In December 2024, Akebia announced that U.S. Renal Care enrolled the first patients in VOICE, a collaborative clinical trial of Vafseo designed to assess mortality and hospitalization in patients ...

Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients.

CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

New Alfa Romeo Stelvio SUV may be set to get petrol power after all New Alfa Romeo Stelvio SUV may be set to get petrol power after all Alfa’s large SUV is still on track, but the outgoing boss ...

Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days ...

72 hr Manufacturer Dornase alfa Pulmozyme (Genentech) 24 hr Prescribing information Epoetin alfa multidose Procrit (Ortho Biotech) 7 days Manufacturer Epoetin alfa single dose Procrit (Ortho ...